carbidopa

Ligand id: 5159

Name: carbidopa

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: carbidopa

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 5
Rotatable bonds 4
Topological polar surface area 115.81
Molecular weight 226.1
XLogP -0.06
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used in the treatment of Parkinson's disease in combination with levodopa. Carbidopa has no antiparkinson actions by itself. A novel delivery method using an intra-intestinal pump to deliver a gel-based formulation of carbidopa+levodopa (called Duodopa®) is in Phase III clinical trial (June 2015).
Mechanism Of Action and Pharmacodynamic Effects
Carbidopa increases the bioavailability of levodopa by;
1- inhibiting peripheral conversion of levodopa to dopamine and
2- inhibiting the metabolism of levodopa in the GI tract.